Prognostic stratification of adult primary glioblastoma multiforme patients based on their tumor gene amplification profiles

• Autor(a) principal: González-Tablas, María
• Data de Publicação: 2018
• Outros Autores: Crespo, Inês, Vital, Ana Luísa, Otero, Álvaro, Nieto, Ana Belén, Sousa, Pablo, Patino-Alonso, María Carmen, Corchete, Luis Antonio, Tão, Hermínio, Rebelo, Olinda, Barbosa, Marcos, Almeida, Maria do Rosário, Guedes, Ana Filipa, Lopes, Maria Celeste, French, Pim J., Orfão, Alberto, Tabernero, María Dolores
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10316/107797; https://doi.org/10.18632/oncotarget.25562
• topic: glioblastoma; classification; subtypes; gene amplification; survival

Several classification systems have been proposed to address genomic heterogeneity of glioblastoma multiforme, but they either showed limited prognostic value and/or are difficult to implement in routine diagnostics. Here we propose a prognostic stratification model for these primary tumors based on tumor gene amplification profiles, that might be easily implemented in routine diagnostics, and potentially improve the patients management. Gene amplification profiles were prospectively evaluated in 80 primary glioblastoma multiforme tumors using single-nucleotide polymorphism arrays and the results obtained validated in publicly available data from 267/347 cases. Gene amplification was detected in 45% of patients, and chromosome 7p11.2 including the EGFR gene, was the most frequently amplified chromosomal region - either alone (18%) or in combination with amplification of DNA sequences in other chromosomal regions (10% of cases). Other frequently amplified DNA sequences included regions in chromosomes 12q(10%), 4q12(7%) and 1q32.1(4%). Based on their gene amplification profiles, glioblastomas were subdivided into: i) tumors with no gene amplification (55%); ii) tumors with chromosome 7p/EGFR gene amplification (with or without amplification of other chromosomal regions) (38%); and iii) glioblastoma multiforme with a single (11%) or multiple (6%) amplified DNA sequences in chromosomal regions other than chromosome 7p. From the prognostic point of view, these amplification profiles showed a significant impact on overall survival of glioblastoma multiforme patients (p>0.001). Based on these gene amplification profiles, a risk-stratification scoring system was built for prognostic stratification of glioblastoma which might be easily implemented in routine diagnostics, and potentially contribute to improved patient management.